I
nflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut, including ulcerative colitis (UC) and Crohn's disease (CD). Epidemiologic studies have shown a stabilized high incidence of IBD in North America and Europe but a continually increasing incidence in previously low-incidence areas, such as Asia. 1 Long-term recurrent gastrointestinal inflammation exerts terrific passive effects on quality of life, which can even cause cancer, becoming a burden on current health care worldwide. Genetic, immune, environmental, and microbial factors could work together in the pathogenesis of IBD, which remains poorly understood. 2 In consideration of the increasingly greater mobility and social economic burden of IBD, seeking a protective mechanism and improving the diagnostic and therapeutic methods would be meaningful.
Recent studies have demonstrated that proteases and their receptors are crucial for chronic gastrointestinal inflammation. 3, 4 Elafin is a low molecular weight antiproteinase believed to antagonize neutrophil elastase, proteinase 3, pancreatic elastase, and endogenous vascular elastase, and otherwise, diverse functions, such as anti-inflammation, immunoregulation, antimicrobe, antiproliferation, vascular remodeling, and tissue repair, have been reported. [5] [6] [7] Recently, 1 study demonstrated that elafin prevented intestinal inflammation in different mouse models of colitis and might be developed as a therapeutic agent for IBD. 8 Another study engineered 2 food-grade strains of lactic acid bacteria to express and deliver elafin at the site of inflammation in the colon. In mouse models of acute and chronic colitis, oral administration of elafin-expressing lactic acid bacteria decreased elastolytic activity and inflammation and restored intestinal homeostasis. 9, 10 The above 2 studies both found that elafin expression in the intestine in IBD decreased; however, an early study showed the opposite result. 11 In addition, the clinical course of IBD is characterized by a succession of relapses and remissions. The activity of the disease can be assessed by clinical manifestations, endoscopic findings, serological indices, or clinical activity scores, such as the modified Mayo score for UC and the Crohn's Disease Activity Index (CDAI) for CD. 12, 13 Among serological indices, Creactive protein (CRP) has been the most widely used and is considered to be a reliable marker of disease activity and response to treatment. 14, 15 Erythrocyte sedimentation rate (ESR) can also reflect disease activity to some extent, but it is inferior to CRP. 16 However, some patients could have clinically active disease, for example, defined by a CDAI greater than 150, and a normal CRP or ESR serum level, which could be attributed to gene polymorphism. 17, 18 Therefore, their value in managing individual patients must be considered in specific clinical contexts. 17 In our study, we detected the expression of elafin not only in colonic tissue but also in the peripheral blood of patients with IBD and then explored its role and value in assessing the activity and severity of IBD, which has never been investigated previously (see Video, Supplemental Digital Content 1, http://links.lww.com/IBD/B628).
MATERIALS AND METHODS

Clinical Samples
Sixty-eight patients with IBD diagnosed with clinical manifestations and colonoscopic and histopathologic findings at Peking University First Hospital were enrolled. Thirty-eight healthy individuals, whose blood routine examinations, routine stool, ESR, CRP, and colonoscopy were normal, served as controls. None of the patients had any other diseases that had been studied before and that could induce changes in elafin expression, such as lung cancer and psoriasis. Two milliliters of peripheral blood were collected from every patient with IBD and control. Biopsy samples of the colonic mucosa were collected, immediately snap frozen in liquid nitrogen, and stored at 2808C until RNA extraction. This study was approved by the ethical committee of First Hospital of Peaking University (No. 20161113), and every patient provided written informed consent. Compared with control group, P , 0.01.
RNA Extraction and qRT-PCR Assays
Total RNA from peripheral blood leukocytes and mucosal epithelial cells were isolated with TRIzol reagent (Life Technologies, Carlsbad, CA). The quality of RNA and the RNA integrity number were determined using RNA 6000NanoLabChip Kits (Agilent Technologies, Santa Clara, CA). qRT-PCR was performed as we described previously. 19 The sequences of primers used in qRT-PCR were as follows: elafin forward: 5 0 -CTTCTTGATCGTGGTGGTGTTC-3 0 and reverse: 5 0 -AACGG-GATCTTGTCCATTGAAT-3 0 , and glyceraldehyde 3-phosphate dehydrogenase forward: 5 0 -GCCTGGTCACCAGGGCT-3 0 and reverse: 5 0 -AATTTGCCATGGGTGGAATC-3 0 .
Immunohistochemical Analysis
Tissue specimens for immunohistochemical analyses were fixed in 10% formalin and were paraffin embedded. The sections were subjected to routine deparaffinization and rehydration. The endogenous peroxidase activity was inhibited by incubation with 3% hydrogen peroxide for 10 minutes. Antigen retrieval was achieved by microwaving in 0.01 mol/L of citrate buffer (pH 9.0) for 25 minutes and then cooling to room temperature. After 3 phosphate-buffered saline washes, the specimens were incubated with rabbit antihuman elafin (1:100; Santa Cruz, CA) at 48C overnight. After incubation with antirabbit IgG horseradish peroxidase (1:100; Dako, Glostrup, Denmark) for 1 hour, signals were developed with 3,3 0 -diaminobenzidine (DAB). The sections were then counterstained with hematoxylin and mounted. Ten fields of vision per section (3 to 4 sections per specimen) were observed blindly at X20 as a semiquantitative assessment for immunohistochemical staining. The elafin staining was evaluated with Image-Pro Plus analysis software (version 6.0; Dallas, TX). The positive signals were quantified as the mean optical density (integrated option density/area).
Enzyme-linked Immunosorbent Assay
The levels of elafin and IL-8 in the plasma of patients with IBD and controls were measured by enzyme-linked immunosorbent assay using commercial kits (Fangcheng Biology, Beijing, China) according to the manufacturer's instructions. The levels of elafin and IL-8 in plasma were expressed in pg/mL.
Statistical Analysis
The normal distribution data are expressed as the mean 6 standard deviation, and non-normal distribution data are expressed as the median (M) (minimum [Min] and maximum [Max] ). Differences were analyzed by Student's t test or the Mann-Whitney U test. The correlations between elafin and other indices (ESR, CRP, and IBD activity score) were analyzed using Spearman's correlation analysis or Pearson's correlation analysis. A P value less than 0.05 was considered significant.
RESULTS
Elafin Expression Decreased in the Peripheral Blood Leukocytes of Patients with IBD
Previous studies have reported that elafin was involved in anti-inflammatory functions, so we sought to examine the role of FIGURE 1. Elafin expression decreased in the peripheral blood leukocytes of patients with IBD. A and B, qRT-PCR analysis of elafin in the peripheral blood leukocytes of patients with IBD (n ¼ 68). C and D, qRT-PCR analysis of elafin in the peripheral blood leukocytes of patients with UC (n ¼ 41). E and F, Expression of elafin mRNA in the peripheral blood leukocytes of patients with CD (n ¼ 27) was examined by qRT-PCR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the housekeeper gene. *P , 0.05, **P , 0.01, and ***P , 0.001. elafin in the pathogenesis of IBD. Sixty-eight patients with IBD and 38 healthy individuals were selected. The average age was 44 6 18 years and 59 6 11 years in the IBD group and control group, respectively. The UC and CD subgroups were staged according to the modified Mayo score and the Best CDAI score, respectively. The IBD group included 41 cases with UC and 27 cases with CD in total. Among these patients, 21 cases were in remission (UC 9 and CD 12), 11 cases were mildly active (UC 5 and CD 6), 15 cases were moderately active (UC 9 and CD 6), and 21 cases were severely active (UC 18 and CD 3) ( Table 1 ). As shown in Table 2 , for the IBD group, the relative expression of elafin mRNA increased in the remission stage and decreased in the active stage, showing a tendency to decrease with increased disease activity. Compared with the controls (Fig. 1A) , the expression of elafin in the IBD remission stage was slightly higher (P ¼ 0.060), and in active IBD, it decreased distinctly (P ¼ 0.034), especially in the moderately and severely active stages (P ¼ 0.003). Compared with the IBD remission stage (Fig. 1B) , the expression of elafin in active IBD was significantly lower (P ¼ 0.001), especially in the severely active stage (P ¼ 0.000). The expression of elafin in active UC also decreased distinctly compared with the controls (P ¼ 0.006) (Fig. 1C) , especially in the moderately (P ¼ 0.037) and severely active stages (P ¼ 0.009), but it was significantly higher in the UC remission stage (P ¼ 0.046). Compared with the UC remission stage (Fig. 1D) , the expression of elafin in active UC was also significantly lower (P ¼ 0.000), especially in the moderately (P ¼ 0.003) and severely active stages (P ¼ 0.001). For the relative expression FIGURE 2. Elafin expression significantly decreased in the inflamed mucosa of patients with IBD. A, Hematoxylin and eosin-stained sections of colons from control (a), noninflammatory sites (b), and inflammatory sites (c) of UC; elafin was determined by immunostaining for controls (d), noninflammatory sites (e), and inflammatory sites (f) of UC. B, The mean optical density of elafin staining in colonic mucosal specimens from patients with IBD (n ¼ 17) and normal individuals (n ¼ 19). C, Relative expression of elafin mRNA in colonic mucosal specimens. Data, mean 6 SD. Original magnification, ·400. *P , 0.05 and **P , 0.01. of elafin mRNA in the CD subgroup (Fig. 1E, F) , the differences among CD remission stages, active stages, and the controls were not significant, either among mildly, moderately, and severely active CD. Although elafin expression in the CD remission stage was lower than in the mildly active stage, in active CD, it still showed a tendency to decrease with increased disease activity (mild versus severe ¼ 0.095).
Elafin Expression Decreased in the Inflamed Colonic Mucosa of Patients with IBD
Immunohistochemical analysis for elafin was performed on paraffin sections of antral biopsy specimens obtained from 17 patients with IBD and 19 controls. As shown in Figure 2A by hematoxylin and eosin staining, compared with the control (a) and noninflammatory mucosa in UC (b), a larger number of inflammatory cells infiltrated the inflammatory mucosa in UC, and the glands were disordered (c). By immunohistochemistry, elafin was expressed in the mucosal surface and glandular ducts and around the inflammatory cells in all of the common mucosa in healthy controls (d) and in the inflamed (f) and noninflamed (e) mucosa of patients with UC. However, the expression of elafin in the inflamed mucosa of patients with UC (f) was lower than that in the common mucosa in controls (d) and lower than that in noninflamed mucosa in UC (f). The mean optical density of elafin staining in the inflamed mucosa of patients with IBD was significantly lower than that in the noninflamed mucosa and normal controls (Fig. 2B) . The expression levels of elafin mRNA also decreased in colonic mucosa specimens from IBD (Fig. 2C) . Collectively, these data indicated that elafin might play a role in the pathogenesis of IBD.
Serum Elafin Expression Decreased in Patients with IBD
Elafin is a secreted protein. The serum elafin concentration was significantly reduced (P ¼ 0.000) (Fig. 3A) , whereas the serum IL-8 level increased (P ¼ 0.000) (Fig. 3B) in patients with IBD. No significant correlation was found between serum IL-8 and elafin through Spearman's correlation analysis. However, there were no significant differences between the remission and active stages of IBD for either elafin or IL-8 (P . 0.05).
Elafin Expression Was Negatively Correlated with Disease Activity
ESR and CRP are commonly used clinical biomarkers, which are helpful for the diagnosis and evaluation of IBD, but there still have many limitations. As shown in Table 3 , the expression of ESR and CRP in IBD active stages was higher, especially in moderately and severely active stages, but in remission stage, it decreased distinctly in UC. Compared with the controls, the expression of ESR and CRP in the CD remission stage was slightly higher.
We next investigated whether there was correlation between elafin expression and disease activity. As shown in Figure 4A , B, the relative expression of elafin mRNA in the peripheral blood leukocytes of the UC subgroup was negatively correlated with ESR (r ¼ 20.391, P ¼ 0.011) and CRP (r ¼ 20.385, P ¼ 0.013). However, there were no significant correlations between the expression of elafin mRNA and the expression of ESR and CRP in the CD subgroup, and the results were r ¼ 20.152, P ¼ 0.450 and r ¼ 20.203, P ¼ 0.311, respectively. The expression of elafin mRNA in the peripheral blood leukocytes of patients with UC and UC disease activity scores (modified Mayo scores) showed a moderately negative correlation (r ¼ 20.450, P ¼ 0.003) (Fig.  4C ), and the relative expression level of elafin mRNA in the CD subgroup was highly negatively correlated with CD disease activity score (Best CDAI score) (r ¼ 20.537, P ¼ 0.004) (Fig. 4D) .
DISCUSSION
IBD is a chronic nonspecific inflammation of the gut, with relatively high morbidity and disability rates. 20 With IBD worldwide at an elevated incidence, it has generated a wide range of socio-economic impacts. 1 Currently, the diagnosis and disease evaluation of IBD depend on endoscopic, histological, and radiological criteria, which are invasive, time consuming, and usually not accepted by patients with IBD. 21 Therefore, finding new biomarkers to diagnose and evaluate IBD is of great importance and the utmost urgency. In our current study, we found that elafin expression decreased in the peripheral blood leukocytes and inflamed colonic mucosa of patients with IBD and was significantly correlated with disease activity.
Elafin is an endogenous, low molecular weight serine protease inhibitor that can specifically inhibit neutrophil elastase, protease 3, pancreatic elastase, and endogenous vascular elastase. It was first isolated from the skin scales of patients with psoriasis. 22 Subsequently, in a variety of human epithelial tissue, such as airway epithelium, gastrointestinal epithelium, and the female genital tract and breast epithelium, elafin has also been found. In addition, it can also be secreted from monocytes, macrophages (alveoli), neutrophils, gdT cells, and other immune cells. 23, 24 It has been reported that elafin participates in the regulation of inflammatory-mediated diseases. Elafin might be an attractive protein involved in IBD. 9, 25 However, earlier studies indicated that the expression of elafin was increased in the colon mucosa of patients with IBD, especially patients with UC. 11, 26 Recently, a study suggested that the expression of elafin decreased in the mucosa of patients with IBD, which could result in increased elastolytic activity in colonic tissue. 9 In our study, downregulated elafin expression in patients with IBD suggested that elafin participates in the pathogenesis of IBD. However, the critical roles of elafin in the pathogenesis of IBD remain unknown. Our results showed that the expression of elafin in patients with active IBD was significantly lower than that in healthy controls, both at the level of gene transcription in peripheral blood leukocytes and at the serum protein level. Combined with the results of immunohistochemistry and qRT-PCR of the colonic tissue, it was confirmed once again that elafin was expressed at low levels in colonic mucosal inflammation sites in IBD, but the expression of elafin in noninflammatory sites in IBD was similar to that in the control group. These results suggested that patients with IBD might be in systemic and/or local intestinal protease/antiprotease imbalance, which could lead to an increase in elastase proteolytic activity and induce intestinal inflammation. Another possibility is that the reduction of elafin was a result of IBD progression rather than the cause. Given that elafin in the digestive tract is mainly secreted from epithelial cells, the destruction of these cells could lead to low expression of elafin. Chronic inflammation also causes elafin consumption. All of the above could lead to a reduction in the molecular level of elafin. However, regardless of whether the reduction in elafin is the cause or consequence of the disease progression of IBD, it is a protective factor for IBD. IL-8 is a proinflammatory chemotactic factor that could be involved in the inflammatory process and might be produced mainly in the lamina propria of the colon and be correlated with mucosal inflammation in IBD. 27, 28 In our study, we found that serum IL-8 increased, whereas serum elafin expression decreased in active IBD, suggesting that, compared with IL-8, elafin might play the opposite anti-inflammatory role in IBD. Furthermore, we observed that serum levels of ESR and CRP significantly increased in active patients with IBD, and elafin expression significantly decreased, which indicated that peripheral blood elafin expression was correlated with disease activity. We found that, at the level of mRNA in peripheral blood leukocytes, the expression of elafin in the UC subgroup was elevated in UC remission and was decreased in active UC, showing a significant tendency to decrease with increased disease activity. However, the expression of elafin in the CD subgroup showed no significant change in disease remission or active stage compared with the control group, but it still revealed a tendency to decrease with increased disease activity in active CD. At the same time, according to the moderately negative correlation between elafin expression and disease activity scores in UC and CD and the mildly negative correlation between elafin expression and ESR/CRP in the UC subgroup, which demonstrated that elafin expression in patients with UC and CD was negatively correlated with endoscopic and clinical disease activity, we have reason to speculate that elafin plays an important role in the induction and development of intestinal inflammation in IBD, and elafin expression could be used to predict IBD disease activity and severity, at least at the mRNA levels in peripheral blood leukocytes. However, we also monitored the expression of elafin at the protein level in plasma, finding only that elafin expression was significantly lower in patients with IBD than in healthy controls, but the differences between diseases in different degrees of activity were not obvious. Further studies are needed.
In conclusion, elafin was reduced in patients with active IBD and was negatively correlated with disease activity. Therefore, elafin could play a protective role in IBD, and elafin expression could be used as an index to evaluate disease activity in IBD.
